Phase I Study of Milatuzumab for Graft Versus Host Disease

NCT01663766 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled

Conditions

GVHD (Acute or Chronic)
Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Myelodysplastic Syndrome
Chronic Myelogenous Leukemia (CML)
Multiple Myeloma (MM)
Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)

Interventions

DRUG: milatuzumab

Sponsor

Gilead Sciences

Collaborators

[object Object]